Innate Pharma (IPHA) Net Income (2019 - 2025)
Innate Pharma's (IPHA) quarterly Net Income came in at -$57.2 million in Q4 2025, down 8.28% YoY from -$62.4 million in Q4 2024, and down 136.93% on a QoQ basis from -$24.2 million in Q2 2025.
Innate Pharma (IPHA) Net Income (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Net Income data on file, last reported at -$57.2 million in Q4 2025.
- Quarterly Net Income fell 8.28% year-over-year to -$57.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$80.9 million (down 1047.21% YoY) and the FY2025 annual result came in at -$57.2 million, down 8.28% from the prior year.
- Net Income slipped to -$57.2 million in Q4 2025, from -$24.2 million in the prior quarter.
- In the past five years, Net Income ranged from a high of $57.1 million in Q2 2021 to a low of -$60.4 million in Q4 2021.
- A 5-year average of -$15.1 million and a median of -$16.2 million in 2025 frame the typical range for Net Income.
- The widest YoY moves for Net Income: up 8523.33% in 2024, down 549.05% in 2024.
- Tracing IPHA's Net Income over 5 years: stood at -$60.4 million in 2021, then increased by 1.87% to -$59.3 million in 2022, then jumped by 86.26% to -$8.1 million in 2023, then tumbled by 549.05% to -$52.9 million in 2024, then decreased by 8.28% to -$57.2 million in 2025.
- The last three Net Income figures came in at -$57.2 million (Q4 2025), -$24.2 million (Q2 2025), and -$52.9 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -355.03 Mn |
| 10 | Innate Pharma | 187.25 Mn | 187.25 Mn | - | -57.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -57.24 Mn |
| Jun 30, 2025 | -24.16 Mn |
| Dec 31, 2024 | -52.86 Mn |
| Jun 30, 2024 | 53.34 Mn |
| Dec 31, 2023 | -8.14 Mn |
| Jun 30, 2023 | 618,509.05 |
| Dec 31, 2022 | -59.28 Mn |
| Jun 30, 2022 | -77,895.14 |
| Dec 31, 2021 | -60.41 Mn |
| Jun 30, 2021 | 57.13 Mn |
| Dec 31, 2020 | -76.29 Mn |
| Jun 30, 2020 | 22.76 Mn |
| Dec 31, 2019 | -22.98 Mn |